BioGend Therapeutics Co., Ltd.
Research BioGend Therapeutics Co., Ltd. (6733.TWO) on Bullrun: market cap TWD 3.28B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6733.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 3.28B
- Financial periodQ2 2026
- RevenueTWD 59.49M
- Net income-TWD 23.92M
- Free cash flow-TWD 12.04M
- Gross margin70.2%
Valuation Snapshot
latest market cap is TWD 3.28B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 3.28B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About BioGend Therapeutics Co., Ltd.
BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia.
ETFs that hold BioGend Therapeutics Co., Ltd.
US-listed ETFs
BioGend Therapeutics Co., Ltd. is held by one US-listed ETF, going by the latest portfolio it filed with the SEC:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
Portfolios as filed with the SEC on Form N-PORT, dated June 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioGend Therapeutics Co., Ltd.'s market cap?
BioGend Therapeutics Co., Ltd.'s market capitalization is TWD 3.28B.
What does BioGend Therapeutics Co., Ltd. do?
BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia. BioGend Therapeutics Co., Ltd. was founded in 2016 and is based in Taipei, Taiwan.